Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
Earnings Data
Report Date
May 19, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress and multiple near-term catalysts: positive preeclampsia interim data (BP and uteroplacental perfusion improvements), Health Canada clearance for a global Phase II early-onset study, encouraging momentum and DSMB clearance in the ReMEDy2 stroke trial, and a strengthened cash position with runway into end-2027. Offsetting these positives are higher cash burn and operating expenses, a regulatory/preclinical complication with the rabbit reproductive tox request that could delay U.S. plans, earlier site staffing delays (now being addressed), and the risk that the stroke program may require a substantially larger sample size (up to 728) if interim results warrant re‑estimation. On balance, the company demonstrated robust scientific and operational progress with manageable but real regulatory, timing and cost risks.Company Guidance
Strong Clinical Signal in Preeclampsia (Part 1a Interim)
Interim Part 1a investigator-sponsored Phase II results (Cohorts 6–9) showed statistically significant, dose-dependent sustained reductions in systolic and diastolic blood pressure and significant reductions in uterine artery pulsatility index (improved uteroplacental perfusion). DM199 did not cross the placental barrier and was not detected in breast milk in the reported patients, supporting a favorable maternal-only exposure/safety profile and potential for earlier/longer treatment to prolong pregnancy.
Regulatory and Trial Advancement for Early-Onset Preeclampsia
Received Health Canada clearance to initiate a global Phase II trial in early-onset preeclampsia (open-label, dose-finding, ~30 participants, 3 dose levels). Plans to finalize site activations in H2 2026 and expand to U.K. sites; Part 1b (up to 30 late-stage) and Part 2 (up to 30 early-onset) protocol amendments are being finalized. Part 1a expansion cohort (up to 12 additional patients) anticipated completion in H1 2026; fetal growth restriction cohort dosing expected in Q2 2026.
ReMEDy2 Stroke Trial Momentum and DSMB Clearance
Enrollment momentum increased with global site activations; trial has achieved almost 70% of the 200 participants required for the interim analysis (implying ~140/200). ~61 active sites (4 U.K., 12 Europe) with ~25 more expected to activate. An independent DSMB reviewed safety data after 100 patients and unanimously recommended continuation without modification. Company reiterated guidance to complete the interim analysis by H2 2026.
Publication and Supporting Data for Blood Pressure Indication
Paper published in Journal of Hypertension highlighting the 'Endothelial Triple Pathway' strategy and referencing prior Phase II REDUX results demonstrating DM199's ability to significantly reduce blood pressure over a 3-month period and lower serum potassium in patients with elevated potassium—supporting potential use in resistant hypertension and CKD populations.
Improved Cash Position and Runway
Cash, cash equivalents and short-term investments increased to $59.9M as of Dec 31, 2025 from $44.1M a year earlier, a $15.8M increase (≈+35.8%). Working capital rose to $55.5M from $39.2M (≈+41.6%). Company expects these funds to finance planned clinical studies and operations through the end of 2027. Net proceeds driven by July 2025 private placement and at-the-market program.
DMAC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DMAC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | $6.64 | $6.77 | +1.96% |
Nov 12, 2025 | $6.31 | $5.42 | -14.10% |
Aug 12, 2025 | $5.22 | $6.00 | +14.94% |
May 13, 2025 | $3.98 | $4.00 | +0.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Diamedica Therapeutics Inc (DMAC) report earnings?
Diamedica Therapeutics Inc (DMAC) is schdueled to report earning on May 19, 2026, TBA (Confirmed).
What is Diamedica Therapeutics Inc (DMAC) earnings time?
Diamedica Therapeutics Inc (DMAC) earnings time is at May 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DMAC EPS forecast?
Currently, no data Available